Drugs / Repinotan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00044915 Comparator | Dec 2000 → Sep 2004 | ischemic stroke | Bayer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Repinotan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00044915 ↗ |
| Known as | BAYX3702 | “Repinotan HCl (BAYX3702)” NCT00044915 ↗ |
| Known as | Repinotan HCl | “Repinotan HCl (BAYX3702)” NCT00044915 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL1614652 ↗ |
| Modality | Small molecule | — CHEMBL1614652 ↗ |
| Route | Intravenous | “Intravenous Repinotan” NCT00044915 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor agonist” CHEMBL1614652 ↗ |